CN1315207A - 一种用重组基因转染的异体皮肤 - Google Patents
一种用重组基因转染的异体皮肤 Download PDFInfo
- Publication number
- CN1315207A CN1315207A CN 00103528 CN00103528A CN1315207A CN 1315207 A CN1315207 A CN 1315207A CN 00103528 CN00103528 CN 00103528 CN 00103528 A CN00103528 A CN 00103528A CN 1315207 A CN1315207 A CN 1315207A
- Authority
- CN
- China
- Prior art keywords
- skin
- cell
- ctla4ig
- transfection
- heterogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 8
- 238000001890 transfection Methods 0.000 claims description 44
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 238000005215 recombination Methods 0.000 claims description 15
- 230000006798 recombination Effects 0.000 claims description 15
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 11
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims description 2
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 241000283898 Ovis Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 230000036573 scar formation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 72
- 210000003491 skin Anatomy 0.000 description 54
- 206010052428 Wound Diseases 0.000 description 28
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 239000000872 buffer Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 16
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 14
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 14
- 238000011534 incubation Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000012531 culture fluid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101150091887 Ctla4 gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000381142 Pachydermia Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001084 no genetic toxicology Toxicity 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000013326 plasmid cotransfection Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000009654 wuzhi Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001035282A CN100387303C (zh) | 2000-03-27 | 2000-03-27 | 一种用于覆盖人烧伤创面的离体的猪皮肤 |
HK02102170.6A HK1042233B (zh) | 2000-03-27 | 2002-03-21 | 一種用於覆蓋人燒傷創面的離體的猪皮膚 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001035282A CN100387303C (zh) | 2000-03-27 | 2000-03-27 | 一种用于覆盖人烧伤创面的离体的猪皮肤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1315207A true CN1315207A (zh) | 2001-10-03 |
CN100387303C CN100387303C (zh) | 2008-05-14 |
Family
ID=4577053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001035282A Expired - Lifetime CN100387303C (zh) | 2000-03-27 | 2000-03-27 | 一种用于覆盖人烧伤创面的离体的猪皮肤 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100387303C (zh) |
HK (1) | HK1042233B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613709B (zh) * | 2008-06-24 | 2013-01-23 | 重庆宗申军辉生物技术有限公司 | 一种利用二乙氨乙基葡聚糖提高基因转染猪皮转染效率的方法 |
CN101613710B (zh) * | 2008-06-24 | 2013-01-23 | 重庆宗申军辉生物技术有限公司 | 一种利用溴化己二甲铵提高基因转染猪皮转染效率的方法 |
WO2017214834A1 (zh) * | 2016-06-14 | 2017-12-21 | 石庆学 | 特异促进 ctla-4 基因高表达的慢病毒表达载体及其应用 |
WO2021143313A1 (zh) * | 2020-01-16 | 2021-07-22 | 深圳市臻质医疗科技有限公司 | 一种用于人皮肤创面覆盖及修复的活性基因改造猪皮肤及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613708B (zh) * | 2008-06-24 | 2013-03-13 | 重庆宗申军辉生物技术有限公司 | 一种利用精蛋白硫酸盐提高基因转染猪皮转染效率的方法 |
-
2000
- 2000-03-27 CN CNB001035282A patent/CN100387303C/zh not_active Expired - Lifetime
-
2002
- 2002-03-21 HK HK02102170.6A patent/HK1042233B/zh not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613709B (zh) * | 2008-06-24 | 2013-01-23 | 重庆宗申军辉生物技术有限公司 | 一种利用二乙氨乙基葡聚糖提高基因转染猪皮转染效率的方法 |
CN101613710B (zh) * | 2008-06-24 | 2013-01-23 | 重庆宗申军辉生物技术有限公司 | 一种利用溴化己二甲铵提高基因转染猪皮转染效率的方法 |
WO2017214834A1 (zh) * | 2016-06-14 | 2017-12-21 | 石庆学 | 特异促进 ctla-4 基因高表达的慢病毒表达载体及其应用 |
WO2021143313A1 (zh) * | 2020-01-16 | 2021-07-22 | 深圳市臻质医疗科技有限公司 | 一种用于人皮肤创面覆盖及修复的活性基因改造猪皮肤及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100387303C (zh) | 2008-05-14 |
HK1042233B (zh) | 2008-12-12 |
HK1042233A1 (en) | 2002-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5847082A (en) | Terminal complement inhibitor fusion proteins | |
CN103102407B (zh) | 基因重组人胶原蛋白 | |
CN101412753A (zh) | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 | |
CN100387303C (zh) | 一种用于覆盖人烧伤创面的离体的猪皮肤 | |
CN101775068A (zh) | 新的天然抗菌肽、其编码序列及用途 | |
CN114134211A (zh) | Usp30基因作为靶点在抑制塞内卡谷病毒复制中的应用 | |
US7335733B2 (en) | Tissue cement proteins from Rhipicephalus appendiculatus | |
JPH05507208A (ja) | 線虫ワクチン | |
CN101343640B (zh) | 共表达CTLA4Ig和CTLA4的重组腺病毒载体、重组腺病毒及其应用 | |
CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
CN1065875C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN1471977A (zh) | 治疗增生性疾病的腺病毒载体与p53基因的基因重组药物 | |
CN1276081C (zh) | 重组人aFGF在家蚕体内基因工程表达生产的方法 | |
CN1277927C (zh) | 家蚕作为宿主生产重组人bFGF的方法 | |
CN1360948A (zh) | 海水鱼二联弧菌灭活疫苗的制备方法 | |
CN108148875B (zh) | 一种基因编辑系统、表达载体、基因编辑试剂盒及其用途 | |
CN115505582B (zh) | 蝶蛹金小蜂毒液犬尿氨酸转氨酶PpVKAT及其应用 | |
PAESEN et al. | Patent 2309355 Summary | |
CN101338313B (zh) | 东方田鼠日本血吸虫抗性基因及其编码的多肽 | |
CN100488568C (zh) | 一种能分泌内皮抑素的细胞制剂及其在制备治疗肿瘤的药中的应用 | |
CN1500810A (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN1443850A (zh) | 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途 | |
CN112175963A (zh) | 一种spp1基因及评估绵羊单卵泡中高尔基体发育质量的方法 | |
CN103305468A (zh) | 一种高表达鼠hdac6的抗病毒感染转基因鼠 | |
CN101818171A (zh) | 人ski基因真核表达载体、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: CHONGQING ZONGSHEN JUNHUI BIOTECHNOLOGY CO.LTD. Free format text: FORMER OWNER: XINAN HOSPITAL, CHONGQING Effective date: 20050325 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050325 Address after: 400054 Chongqing city Banan District fry oil field Zongshen Industrial Park Chongqing Zongshen Junhui Biotechnology Co. Ltd. Applicant after: Chongqing Zhongshenjunhui Biology Technology Co., Ltd. Address before: 400038 Chongqing Shapingba gaotanyan Applicant before: Chongqing Xi'nan Hospital |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1042233 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: CHONGQING DAQING YICHENG BIOTECHNOLOGY CO. LTD. Free format text: FORMER NAME: CHONGQING ZHONGSHENJUNHUI BIOLOGY TECHNOLOGY CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Bridge Industrial Park 400084 Dadukou District of Chongqing Patentee after: Chongqing Daqing Yicheng Biological Technology Co., Ltd. Address before: 400054 Chongqing city Banan District fry oil field Zongshen Industrial Park Chongqing Zongshen Junhui Biotechnology Co. Ltd. Patentee before: Chongqing Zhongshenjunhui Biology Technology Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20080514 |
|
CX01 | Expiry of patent term |